Drug intelligence / Profile preview

dachaihu decoction + erzhiwan

Development stage
Phase 2
Modality
Small Molecules
Administration
Oral
01

Overview

Dachaihu Decoction + Erzhiwan is a combination of two classic traditional Chinese medicine (TCM) formulas. Dachaihu Decoction (Da Chai Hu Tang, Major Bupleurum Decoction) is an ancient herbal formula originating from the "Treatise on Cold Damage and Miscellaneous Diseases" by Zhongjing Zhang during the Eastern Han Dynasty. It contains eight herbs including Bupleurum Root (Chai Hu), Rhubarb (Da Huang), Chinese Skullcap Root (Huang Qin), Immature Bitter Orange (Zhi Shi), Pinellia Rhizome (Ban Xia), White Peony Root (Bai Shao), Ginger (Sheng Jiang), and Jujube Fruit (Da Zao). Its main actions are to harmonize and release the Lesser Yang stage while draining internal clumping due to heat. Mechanistically, it targets multiple pathways involved in inflammation, liver protection, bile flow promotion, lipid metabolism regulation, and immune modulation—affecting signaling such as MAPK/ERK1/2 cascade and NF-κB activity[2][5][7]. Erzhiwan ("Two Ultimate Pill") is another classical TCM formula composed mainly of Ligustrum lucidum fruit ("Nu Zhen Zi") and Eclipta prostrata herb ("Han Lian Cao"). It is traditionally used for nourishing liver and kidney yin deficiency. The combination has been studied in clinical trials for conditions such as hypercholesterolemia[1], nonalcoholic fatty liver disease/metabolic associated fatty liver disease[2], acute cholecystitis[7], acute pancreatitis[5][8][9], type 2 diabetes mellitus, angina pectoris, cholecystitis/cholelithiasis/pancreatitis patterns in TCM theory. The mechanisms involve anti-inflammatory effects via reduction of cytokines like TNF-α/IL-6/IL-8/CRP; improvement of lipid metabolism; hepatoprotection; regulation of gut microbiota; antioxidative effects; modulation of glucose metabolism; angiogenesis inhibition; immunomodulation through various molecular targets including JUN/TNF/EGFR/MAPK3/SIRT1/HIF1A.

Other names
dachaihu decoction + erzhiwanda chai hu tang + erzhi wanmajor bupleurum decoction + erzhiwan
02

Targets

IL-6 (Interleukin 6)NF-κBTNFA (Tumor necrosis factor alpha (soluble))MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on dachaihu decoction + erzhiwan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dachaihu decoction + erzhiwan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call